加味逍遥丸配合乳腺病治疗仪治疗乳腺增生疗效观察

目的探讨加味逍遥丸配合乳腺病治疗仪治疗乳腺增生临床疗效。方法采用加味逍遥丸配合乳腺病治疗仪治疗乳腺增生症,佐以病因治疗。结果采用以上方法治疗各种类型乳腺增生症患者80例,取得满意疗效,总有效率96.25%。结论乳腺增生症采用中成药与乳腺病治疗仪综合治疗方法是可行的,但对于乳腺囊性增生患者尚有待进一步探索治疗方法,提高疗效。     

广州市荔湾区育龄妇女乳腺疾病筛查情况分析

应用近红外线乳腺扫描技术及乳房外科体检对11 615例育龄妇女进行乳腺疾病筛查.发现乳腺病疾病中发病率乳腺增生占首位,其他依次为乳腺纤维腺瘤、乳腺囊肿、乳腺癌、乳腺叶状肿瘤、乳管内乳头状瘤,其中乳腺癌的发病率为34.44/10万.认为乳腺疾病是育龄妇女的常见病、多发病,乳腺癌的发病率呈上升趋势,应将乳腺疾病的筛查常规纳入妇女病普查普治中.     

艾灸配中药治疗乳腺增生

乳腺增生是临床乳腺病中最常见的疾病 ,在中医学中属“乳癖”范畴。一般认为冲任失调与肝气郁滞为发病的主要原因。笔者 ,1997年以来 ,采用艾灸配中药治疗 6 8例 ,取得满意效果。1　临床资料共观察 6 8例患者 ,均为未绝经期女性。年龄 2 1岁～ 5 0岁 ,病程最短 1月 ,最长 15年 ,其中 1年以内者 36例。自感乳房轻微胀痛 ,扪及增生结节 0 .5 cm× 1.0 cm为轻度增生 2 4例。自感乳房胀痛 ,扪及增生结节 1.1cm× 1.5 cm为中度增生36例。自感乳房明显胀痛 ,扪及增生结节 1.6 cm× 2 .0 cm为重度增生 8例。全部病例均经 B超及红外线检查排除恶性…     

止痛消乳汤治疗乳腺增生105例临床疗效观察

止痛消乳汤治疗乳腺增生１０５例临床疗效观察太原日用化学总厂智素娥山西中医学院附院（０３００２４）李如琴从１９８８年至１９９３年底，笔者用自拟的止痛消乳汤治疗乳腺病１０５例，收到了较好的疗效，现总结如下。－、临床资料１０５例乳腺增生患者均为门诊就诊的女...     

中西医结合治疗乳腺增生结节的疗效分析

目的探讨手术联合乳癖散结胶囊治疗乳腺增生结节的疗效。方法将患者按随机方法分为治疗组169例和对照组168例,所有患者均实施常规性的乳腺肿块、乳腺区段切除手术。治疗组在手术治疗基础上,饭后给予乳癖散结胶囊口服治疗。观察两组患者的疗效与不良反应发生情况。结果治疗组的总有效率为87.5%高于对照组的69.1%,差异有统计学意义(P0.05);治疗组患者有3例(4.3%)月经量85 m L且经期较长,无其他不良反应症状,两组不良反应发生情况比较差异无统计学意义(P0.05)。结论手术联合乳癖散结胶囊治疗乳腺增生结节,疗效显著,副作用轻,建议临床推广应用。     

乳腺康贴剂治疗乳腺增生临床效果观察

目的 观察乳腺康贴剂通过乳房帖敷靶向治疗乳腺增生的临床效果.方法 取猫爪草、元胡、天葵子、山慈菇、凤仙子、香附、皂角、木鳖子、三棱、橘仁10味中药材,经乙醇浸泡提取后制成乳腺康贴剂.将贴剂贴于85例乳腺增生患者乳房的肿块和痛点显著处,每2d更换1次,30 d为一疗程,共治疗2个疗程.根据中华中医外科学会乳腺病专业委员会制定的《乳腺增生病诊断、辨证及疗效判定标准》判断疗效.结果 本组治愈70例,治愈率为82.35％;13例显效,显效率为15.29％;2例有效,有效率为2.36％;总有效率为100％.治疗过程中均未出现不良反应.结论 乳腺康贴剂帖敷对乳腺增生具有较好的治疗作用,使用方便,无明显不良反应.     

乳腺导管原位癌保乳手术治疗的疗效分析

目的分析乳腺导管原位癌保乳手术治疗的疗效。方法选取我院2015年10月~2016年5月收治的乳腺癌患者84例作为研究对象,对所有患者进行影像学检查以及细胞组织学检查后明确乳腺癌类型,比较乳腺导管原位癌患者以及Ⅰ、Ⅱ期乳腺浸润性导管癌患者均进行保乳手术加放化疗治疗后患者的预后情况。结果术后乳腺导管原位癌患者48例中有2例粉刺型复发,有1例非粉刺型复发,Ⅰ、Ⅱ期乳腺浸润性导管癌患者术后复发率为19.4%,差异有统计学意义(P0.05)。结论对乳腺导管原位癌患者行保乳手术治疗与其Ⅰ、Ⅱ期乳腺浸润性导管癌相比,复发率低,且复发患者中粉刺型乳腺导管原位癌的复发率较高。     

关于糖尿病患者合并乳腺病的治疗及综合护理一体化分析

随着我国社会医疗技术的发展,提升医患的治疗水平成为了特点话题。人们生活水平在近些年来获得较大改善,而糖尿病的患者的数量呈现较快的上升速度,在乳腺科治疗过程中就发现存在乳腺病和糖尿病合并患者,这就要求在诊治过程中需要兼顾两种病理特征,从患者需求和全方位治疗出发,这就需要提供治疗及护理一体化的治疗方案。该文就是结合日常治疗工作中的具体经验,探索糖尿病患者合并乳腺病的治疗及综合护理一体化方案,从而为糖尿病患者合并乳腺病患者提供更好的治疗支持。     

卡托普利联合他莫昔芬治疗乳腺增生伴高血压的临床疗效及对雌二醇、黄体酮水平的影响

目的观察卡托普利联合他莫昔芬治疗乳腺增生伴高血压的临床疗效及对雌二醇、黄体酮水平的影响。方法乳腺增生伴高血压患者160例随机分为观察组和对照组,每组80例。对照组给予乳癖消片联合卡托普利片治疗,乳癖消片6片/次,3次/d;卡托普利1片/次,3次/d;观察组给予他莫昔芬联合卡托普利片治疗,他莫昔芬1片/次,2次/d;卡托普利1片/次,3次/d;两组患者持续治疗6个月。比较两组治疗后的临床疗效、血压情况、雌激素水平和不良反应发生情况。结果治疗后,观察组治疗有效率明显高于对照组(95.00%vs 80.00%,P<0.05);对照组和观察组雌二醇[对照组:治疗后(43.53±5.28)pmol/L vs治疗前(50.03±6.42)pmol/L;观察组:治疗后(32.23±3.18)pmol/L vs治疗前(50.94±6.88)pmol/L]和黄体酮[对照组:治疗前(54.52±6.15)nmol/L vs治疗后(43.23±4.45)nmol/L;观察组:治疗前(55.13±6.38)nmol/L vs治疗后(31.43±3.58)nmol/L]水平明显优于治疗前,并且观察组改善程度显著高于对照组(均P<0.05)。在治疗期间,观察组患者调整剂量剂次(2例次)和血压波动例次(1例次)显著低于对照组(7例次、5例次;χ~2=4.684,P<0.05;χ~2=3.212,P<0.05)。对照组和观察组不良反应发生率差异无统计学意义(P>0.05)。结论卡托普利联合他莫昔芬治疗能稳定乳腺增生伴高血压患者的血压水平,改善患者雌激素水平。     

美迪克乳腺病保健治疗仪治疗乳腺病306例

1999年 1月至 2 0 0 0年 12月 ,我们采用美迪克乳腺病保健治疗仪 (以下简称治疗仪 )治疗乳腺疾病 30 6例 ,效果较满意。现报告如下。资料与方法 :30 6例患者中急性乳腺炎 6 0例 ,年龄 2 2～32岁 ,平均 2 4.8岁 ;乳腺增生病 196例 ,年龄 2 9～ 46岁 ,平均34.5岁 ;乳腺纤维瘤 5 0例 ,年龄 18～ 38岁 ,平均 2 6 .6岁。乳腺增生病、乳腺纤维瘤主要依靠病史、症状、体征和电脑近红外光乳腺诊断仪检查确诊。急性乳腺炎根据《实用妇产科学》并参考有关文献制定的诊断标准确诊。治疗方法 :先将治疗仪治疗头与机箱连接好 ,打开电源开关 ,再打开治疗头…     

促凋亡蛋白BAD在乳腺导管增生及乳腺癌组织中表达的研究

目的检测促凋亡蛋白BAD在人乳腺导管增生及乳腺癌组织中表达,探讨其在乳腺癌癌变过程中的作用及意义.方法采用免疫组织化学S-P法,检测131例乳腺导管增生及乳腺癌组织中促凋亡蛋白BAD的表达.结果BAD蛋白在正常乳腺组织中的阳性率为33.3%（3/9）.从普通导管增生、轻中度不典型导管增生、重度不典型增生及导管原位癌到浸润性导管癌组织,BAD蛋白表达阳性率呈递增趋势,在乳腺普通导管增生和重度不典型增生及原位癌组间阳性表达率差异均具有统计学意义（P＜0.05）.结论促凋亡蛋白BAD蛋白表达在乳腺癌癌变过程中呈递增趋势;BAD蛋白表达水平与组织学分级有关,组织学分级越低,其蛋白表达阳性率越高.     

日本血吸虫病相关胃肠道肿瘤的临床与病理特征

目的了解慢性肠道血吸虫感染与肠道肿瘤发生的关系。方法回顾分析池州市人民医院2005年1月~2013年3月慢性胃肠道血吸虫感染合并胃肠道肿瘤患者病理资料,总结慢性血吸虫胃肠道感染患者并发胃肠道肿瘤发生情况,分析慢性血吸虫胃肠道感染与胃肠道肿瘤发生的特点。结果慢性血吸虫病并发胃肠道肿瘤的比例为25.8%(88/340),其中癌发生比例为22.6%(77/340),轻度不典型增生为0.58%(2/340),中度不典型增生为1.47%(5/340),重度不典型增生为1.17%(4/340)。结论肠道慢性血吸虫感染与胃肠道肿瘤发生有关,可能为癌前病变。     

Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands

To test directly the role of breast-tissue estrogen in initiation of breast cancer, we have developed the aromatase-transgenic mouse model and demonstrated for the first time that increased mammary estrogens resulting from the overexpression of aromatase in mammary glands lead to the induction of various preneoplastic and neoplastic changes that are similar to early breast cancer. Continued overexpression of aromatase that leads to increased breast-tissue estrogen contributes to a number of epigenetic changes in mammary tissue such as alteration in the regulation of genes involved in apoptosis, activation of genes involved in cell cycle and cell proliferation, and activation of a number of growth factors. Our current studies show aromatase overexpression is sufficient to induce and maintain early preneoplastic and neoplastic changes in female mice without circulating ovarian estrogen. Preneoplastic and neoplastic changes induced in mammary glands as a result of aromatase overexpression can be completely abrogated with the administration of the aromatase inhibitor, letrozole. Consistent with complete reduction in hyperplasia, we have also seen downregulation of estrogen receptor and a decrease in cell proliferation markers, suggesting aromatase-induced hyperplasia can be treated with aromatase inhibitors. Our studies demonstrate that aromatase overexpression alone, without circulating estrogen, is responsible for the induction of breast hyperplasia and these changes can be abrogated using aromatase inhibitors.     

Premalignant and in situ breast disease: biology and clinical implications

Most types of invasive breast cancer are thought to evolve over long periods from specific preexisting benign lesions. Of the many types of benign entities found in the human breast, only a few have clinically significant premalignant potential. Currently, the best-characterized premalignant lesions are atypical ductal hyperplasia, atypical lobular hyperplasia, and lobular carcinoma in situ. Ductal carcinoma in situ is considered to be a preinvasive malignant lesion. Two additional lesions, unfolded lobules and usual ductal hyperplasia, are sometimes considered to be very early premalignant epithelial abnormalities. Premalignant lesions are currently defined by their histologic features, and not all necessarily progress to invasive cancer. This suggests that although lesions within specific categories look alike, they must possess underlying genetic differences that cause some to remain stable and others to advance. The development of modern molecular genetic techniques has allowed breast cancer researchers to clarify the multistep model of breast carcinogenesis. Recent studies indicate that cancer evolves by highly diverse genetic mechanisms, and research into these altered pathways may identify specific early defects that might be targeted to prevent progression of premalignant lesions to invasive cancer. Current clinical management is heterogeneous and depends on histologic examination and individual patient factors. Options for breast cancer risk reduction and prevention are available.     

CEA mRNA在乳腺癌患者外周血中的表达及临床意义

目的以套式RT—PCR方法检测癌胚抗原（CEA）mRNA在乳腺癌患者外周血中的表达，并探讨其在乳腺癌诊断与治疗中的意义。方法收集乳腺癌患者52例（乳腺癌组）、乳腺增生性病变患者40例（增生组）、健康查体者20例（对照组），采集外周血样本。分别用套式RT—PCR法检测其外周血中CEAmRNA的表达。结果乳腺癌组外周血CEAmRNA阳性率为40．4％，增生组及对照组分别为5．0%和0，两两比较均有显著差异（P均〈0．01）；乳腺癌组TNMⅢ期、Ⅳ期患者CEAmRNA阳性表达率明显高于Ⅰ期、Ⅱ期患者，外周血CEAmRNA阳性表达与淋巴结转移密切相关。结论外周血CEAmRNA表达可作为乳腺癌转移的一个辅助监测指标。     

The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis

Purpose  

Benign breast disease (BBD) is an important risk factor for subsequent breast cancer. However, it is unclear whether breast cancer risk is higher in cases of atypical ductal hyperplasia (ADH) than atypical lobular hyperplasia (ALH). Furthermore, it is unclear whether family history increases risk in women with various subtypes of BBD.     

Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury

Azathioprine is a useful agent for the treatment of Crohn's disease but side effects occur in 10% of patients. Hepatic toxicity is well recognized and is usually associated with abnormalities of liver function tests. We describe a female patient who was on azathioprine for the treatment of Crohn's disease for a total of 216 months. She developed portal hypertension complicated by variceal haemorrhage. This required the insertion of a trans-jugular intra-hepatic porto-systemic shunt to control the bleeding. Subsequent histology has shown mild nodular regenerative hyperplasia, and other causes of liver disease have been excluded. The only liver function abnormalities were mild elevation of bilirubin and a low albumin in the later stages.     

A 47-year-old stem cell transplant recipient with fever,cough and chest pain

Infections and malignancies are among the most serious complications that follow organ or stem cell transplantation. They may have a mild course, and nonspecific and overlapping manifestations. The present article describes a case of symptomatic nodular pulmonary disease that complicated hematopoietic stem cell transplantation. It was diagnosed to be post-transplant lymphoproliferative disorder, a potential sequela of immunosuppression and a very difficult entity to treat in profoundly immunosuppressed patients.     

Characterization of a preleukemic state induced by Moloney murine leukemia virus: evidence for two infection events during leukemogenesis.

A preleukemic state in mice inoculated with Moloney murine leukemia virus (Mo-MuLV) was characterized. Six to 10 weeks after neonatal inoculation, animals developed mild splenomegaly and generalized hematopoietic hyperplasia. The hyperplasia was evident from myeloid and erythroid progenitor assays. A nonleukemogenic variant, Mo+PyF101 Mo-MuLV, did not induce the hyperplasia; this suggests that the hyperplasia is a necessary event in Mo-MuLV leukemogenesis. Another variant, MF-MuLV, which contains the long terminal repeat of Friend MuLV and causes erythroid leukemia instead of T-cell lymphoma, also induced the preleukemic hyperplasia. A model for Mo-MuLV leukemogenesis is presented in which two infection events are necessary: the first leads to generalized hematopoietic hyperplasia, and the second results in site-specific insertion and long terminal repeat activation of cellular protooncogenes.     

Treatment of benign prostatic hyperplasia in hypertensive men

As the proportion of the US population over the age of 65 continues to rise, it is likely that the number of individuals with concomitant benign prostatic hyperplasia and hypertension will also increase. To reduce morbidity and mortality, it is important to treat patients with hypertension optimally. Evidence from outcome trials suggests that alpha1 blockers should not be used as first-line antihypertensive therapy. Although some clinicians previously recommended alpha1 blocker monotherapy for patients with both hypertension and benign prostatic hyperplasia, the most recent American Urologic Association and Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines recommend independent treatment with the most appropriate pharmacologic agents for each condition. When treating patients with benign prostatic hyperplasia, clinicians should be aware of the potential impacts that alpha1 blockers may have on blood pressure and potential adverse events in patients who are normotensive as well as in patients with treated hypertension.